285 related articles for article (PubMed ID: 28228114)
1. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.
Vizza CD; Sastry BK; Safdar Z; Harnisch L; Gao X; Zhang M; Lamba M; Jing ZC
BMC Pulm Med; 2017 Feb; 17(1):44. PubMed ID: 28228114
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
Hoeper MM; Ewert R; Jansa P; Sirenko Y; Skride A; Balagtas C; Hackley S; Vogt S; Abreu P; Haughie S; Hassan T; Oudiz RJ
Circulation; 2024 Jun; 149(25):1949-1959. PubMed ID: 38752352
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
Rubin LJ; Badesch DB; Fleming TR; Galiè N; Simonneau G; Ghofrani HA; Oakes M; Layton G; Serdarevic-Pehar M; McLaughlin VV; Barst RJ;
Chest; 2011 Nov; 140(5):1274-1283. PubMed ID: 21546436
[TBL] [Abstract][Full Text] [Related]
5. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.
Barst RJ; Beghetti M; Pulido T; Layton G; Konourina I; Zhang M; Ivy DD;
Circulation; 2014 May; 129(19):1914-23. PubMed ID: 24637559
[TBL] [Abstract][Full Text] [Related]
6. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
7. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.
Barst RJ; Ivy DD; Gaitan G; Szatmari A; Rudzinski A; Garcia AE; Sastry BK; Pulido T; Layton GR; Serdarevic-Pehar M; Wessel DL
Circulation; 2012 Jan; 125(2):324-34. PubMed ID: 22128226
[TBL] [Abstract][Full Text] [Related]
9. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
10. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.
Wirostko BM; Tressler C; Hwang LJ; Burgess G; Laties AM
BMJ; 2012 Feb; 344():e554. PubMed ID: 22354598
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
Vitulo P; Stanziola A; Confalonieri M; Libertucci D; Oggionni T; Rottoli P; Paciocco G; Tuzzolino F; Martino L; Beretta M; Callari A; Amaducci A; Badagliacca R; Poscia R; Meloni F; Refini RM; Geri P; Baldi S; Ghio S; D'Alto M; Argiento P; Sofia M; Guardamagna M; Pezzuto B; Vizza CD
J Heart Lung Transplant; 2017 Feb; 36(2):166-174. PubMed ID: 27329400
[TBL] [Abstract][Full Text] [Related]
13. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
McLaughlin V; Channick RN; Ghofrani HA; Lemarié JC; Naeije R; Packer M; Souza R; Tapson VF; Tolson J; Al Hiti H; Meyer G; Hoeper MM
Eur Respir J; 2015 Aug; 46(2):405-13. PubMed ID: 26113687
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.
Beghetti M; Rudzinski A; Zhang M
BMC Cardiovasc Disord; 2017 Jul; 17(1):177. PubMed ID: 28676038
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil Versus Placebo for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS): protocol for a randomized controlled trial.
Lammi MR; Mukherjee M; Saketkoo LA; Carey K; Hummers L; Hsu S; Krishnan A; Sandi M; Shah AA; Zimmerman SL; Hassoun PM; Mathai SC
BMC Pulm Med; 2024 Apr; 24(1):211. PubMed ID: 38689245
[TBL] [Abstract][Full Text] [Related]
16. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
Frantz RP; McDevitt S; Walker S
J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
[TBL] [Abstract][Full Text] [Related]
17. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
Bermejo J; Yotti R; García-Orta R; Sánchez-Fernández PL; Castaño M; Segovia-Cubero J; Escribano-Subías P; San Román JA; Borrás X; Alonso-Gómez A; Botas J; Crespo-Leiro MG; Velasco S; Bayés-Genís A; López A; Muñoz-Aguilera R; de Teresa E; González-Juanatey JR; Evangelista A; Mombiela T; González-Mansilla A; Elízaga J; Martín-Moreiras J; González-Santos JM; Moreno-Escobar E; Fernández-Avilés F;
Eur Heart J; 2018 Apr; 39(15):1255-1264. PubMed ID: 29281101
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
[TBL] [Abstract][Full Text] [Related]
20. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
